Genentech and Parvus Therapeutics Collaborate on Autoimmune Diseases

By Michelle Liu

Pharma Deals Review: Vol 2019 Issue 5 (Table of Contents)

Published: 22 May-2019

DOI: 10.3833/pdr.v2019.i5.2426     ISSN: 1756-7874

Section: Licensing



In an effort to expand its autoimmune pipeline, Genentech has agreed to collaborate with Parvus Therapeutics to develop and commercialise therapeutics for the treatment of inflammatory bowel disease, autoimmune liver diseases, and celiac disease...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details